Acorda Therapeutics Inc.

0.5237-0.0402-7.13%Vol 915.01K1Y Perf -88.74%
Jun 24th, 2022 16:00 DELAYED
BID0.5110 ASK0.5526
Open0.5630 Previous Close0.5639
Pre-Market- After-Market0.55
 - -  0.03 5.38%
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
1.81K 
Finscreener Ranking
★★+     48.00
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★+     44.80
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
+     30.61
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
4.07 
Earnings Rating
Buy
Market Cap12.71M 
Earnings Date
4th Aug 2022
Alpha-0.06 Standard Deviation0.24
Beta0.50 

Today's Price Range

0.52060.5900

52W Range

0.27636.36

5 Year PE Ratio Range

-18.1024.70

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-17.53%
1 Month
27.73%
3 Months
-69.90%
6 Months
-78.00%
1 Year
-88.74%
3 Years
-98.76%
5 Years
-99.55%
10 Years
-99.62%

TickerPriceChg.Chg.%
ACOR0.5237-0.0402-7.13
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.00
1.70
0.59
1.52
-2.20
Leverage Ratio 2.90
ProfitabilityValueIndustryS&P 500US Markets
71.70
-54.60
-26.90
-91.60
-77.76
RevenueValueIndustryS&P 500US Markets
122.74M
5.06
-26.88
-28.47
Earnings HistoryEstimateReportedSurprise %
Q01 2022--1.93-
Q04 2021--1.73-
Q03 2021--2.43-
Q02 2021-2.09-2.29-9.57
Q01 2021-3.71-3.534.85
Q04 2020-2.579.82482.10
Q03 2020-2.820.30110.64
Q02 2020-3.84-2.2242.19
Earnings Per EndEstimateRevision %Trend
9/2021 QR-1.560.00-
12/2021 QR-1.110.00-
12/2021 FY-7.640.00-
12/2022 FY-0.960.00-
Next Report Date4th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume915.01K
Shares Outstanding24.28K
Shares Float24.12M
Trades Count1.35K
Dollar Volume503.24K
Avg. Volume3.70M
Avg. Weekly Volume4.80M
Avg. Monthly Volume4.68M
Avg. Quarterly Volume1.63M

Acorda Therapeutics Inc. (NASDAQ: ACOR) stock closed at 0.5237 per share at the end of the most recent trading day (a -7.13% change compared to the prior day closing price) with a volume of 915.01K shares and market capitalization of 12.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 168 people. Acorda Therapeutics Inc. CEO is Ron Cohen.

The one-year performance of Acorda Therapeutics Inc. stock is -88.74%, while year-to-date (YTD) performance is -78.09%. ACOR stock has a five-year performance of -99.55%. Its 52-week range is between 0.27625 and 6.36, which gives ACOR stock a 52-week price range ratio of 4.07%

Acorda Therapeutics Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.12, a price-to-sale (PS) ratio of 0.13, a price to cashflow ratio of 7.40, a PEG ratio of 2.32, a ROA of -19.48%, a ROC of -16.87% and a ROE of -58.96%. The company’s profit margin is -77.76%, its EBITDA margin is -26.90%, and its revenue ttm is $122.74 Million , which makes it $5.06 revenue per share.

Of the last four earnings reports from Acorda Therapeutics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Acorda Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Acorda Therapeutics Inc. is Strong Buy (1), with a target price of $10, which is +1 809.49% compared to the current price. The earnings rating for Acorda Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Acorda Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Acorda Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.55, ATR14 : 0.11, CCI20 : 70.59, Chaikin Money Flow : -0.20, MACD : -0.05, Money Flow Index : 79.36, ROC : 44.27, RSI : 46.38, STOCH (14,3) : 47.53, STOCH RSI : 0.61, UO : 45.48, Williams %R : -52.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Acorda Therapeutics Inc. in the last 12-months were: Ron Cohen (Sold 2 289 shares of value $3 895 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Acorda Therapeutics Inc.

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.

CEO: Ron Cohen

Telephone: +1 914 347-4300

Address: 420 Saw Mill River Road, Ardsley 10502, NY, US

Number of employees: 168

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

65%35%

Bearish Bullish

61%39%

News

Stocktwits